Art

J-GLOBAL ID：201702282258158149   Reference number：17A0571265

Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials

第3相臨床治験における毎週1回のデュラグルチド0.75mgで最大52週間治療された2型糖尿病の日本人患者における膵安全性

Author (5)： Emoto Masanori (Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan) ,  Oura Tomonori (Eli Lilly Japan K.K., Kobe 651-0086, Japan) ,  Matsui Akiko (Eli Lilly Japan K.K., Kobe 651-0086, Japan) ,  Kazama Hirotaka (Eli Lilly Japan K.K., Kobe 651-0086, Japan) ,  Iwamoto Noriyuki (Eli Lilly Japan K.K., Kobe 651-0086, Japan)
Material： Endocrine Journal  (Endocr J)
Volume： 64  Issue： 2  Page： 191-206(J-STAGE)  Publication year： 2017 
JST Material Number： F0625A  ISSN： 0918-8959  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： *デュラグルチド

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0571265&from=J-GLOBAL&jstjournalNo=F0625A") }}

Author keywords (5)： Dulaglutide ,  GLP-1 receptor agonist ,  Type 2 diabetes ,  Pancreatitis ,  Japanese

JST classification (2)： Treatment for metabolic diseases,nutritional diseases.  (GD05030F) ,  Clinical application of drugs acting on carbohydrate metabolism  (GW13030B)

Reference (34)：

• 1. Azoulay L (2015) Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains. Diabetes Care 38: 951-953.
• 2. Gale EA (2015) Smoke or fire? Acute pancreatitis and the liraglutide trials. Diabetes Care 38: 948-950.
• 3. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141: 150-156.
• 4. Dore DD, Seeger JD, Arnold Chan K (2009) Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 25: 1019-1027.
• 5. Garg R, Chen W, Pendergrass M (2010) Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: A retrospective observational pharmacy claims analysis. Diabetes Care 33: 2349-2354.

Terms in the title (9)： 3相 ,  臨床治験 ,  デュラグルチド ,  治療 ,  2型糖尿病 ,  日本人 ,  患者 ,  膵 ,  安全性